Mainz Biomed NV
Mainz Biomed NV (MYNZ) is a small, micro‑cap diagnostics company focused on developing molecular tests using epigenetic and other biomarker approaches. The firm’s work centres on early detection and monitoring of diseases via blood‑based assays; such businesses rely on clinical validation, regulatory progress and commercial partnerships to scale. With a market capitalisation of roughly $8.4m, Mainz Biomed is a high‑volatility, low‑liquidity stock where outcomes hinge on trial results, approvals and funding. Potential upside exists if diagnostic tests achieve regulatory clearance and market adoption, but investors should weigh that against common biotech risks: clinical failure, competitive pressure and the likelihood of additional capital raises. This summary is educational only and not investment advice — always review the company’s filings, recent results and analyst coverage, and consider your risk tolerance and time horizon before investing.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Mainz Biomed's stock with a target price of $4, indicating strong growth potential.
Financial Health
Mainz Biomed is generating modest revenue and cash flow, but its profitability potential is still developing.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring MYNZ
German Stocks Soaring
Discover a carefully selected collection of German companies that have been dramatically outperforming their western counterparts. Our team of professional analysts has identified these standout stocks as Germany's economy shows promising signs of growth in 2025.
Published: May 15, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline‑driven upside
Clinical milestones and regulatory updates can be catalysts for share moves, though outcomes are uncertain and can be volatile.
Market and adoption
Commercial adoption in diagnostics markets could support growth, but competition and reimbursement barriers mean success is not guaranteed.
Balance sheet watch
With a very small market cap, cash runway and funding plans are key; investors should expect possible dilution if capital is required.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
